2.6M
Medical community members
100.000
Curated content pieces
60M+
Monthly pageviews
See more
Oncologia Brasil
A recent publication in npj Precision Oncology marks a milestone in translational oncology: the multicenter validation of OncoSeek, an artificial intelligence–driven blood test capable of detecting up to 14 types of cancer early, with high accuracy, low cost, and scalability even in low-resource settings.Led by an international consortium of researchers from China, the United States, and Brazil, the study enrolled 15,1
Artificial Intelligence
Oncology
9 out, 2025
6min
A study published in the Journal of Cancer Research and Clinical Oncology (2025) by Li et al. introduced a machine learning–based approach to predict hepatocellular carcinoma (HCC) development among patients with hepatitis B virus (HBV)-related compensated advanced chronic liver disease (cACLD) — a stage where fibrosis and portal hypertension progress despite preserved liver function.The retrospective cohort included 1
5min
Rafael Mantovani
A landmark economic evaluation published in Value in Health (October 2025) by Dayer et al. quantified the long-term clinical and financial impact of broad semaglutide access within the Medicare population, encompassing current and anticipated FDA-approved uses — type 2 diabetes (T2D), obesity, and metabolic-associated steatohepatitis (MASH). Using real-world claims, government data, and published clinical outcomes, the study modeled 10-year o
Farmacoeconomics
Public Health
7min
A comprehensive systematic review and meta-analysis published in Value in Health (October 2025) by Oyemakinde et al. provides the first aggregated synthesis of cost per opioid-free year (OfY) as an alternative to quality-adjusted life years (QALY) in evaluating opioid use disorder (OUD) interventions. This metric—reflecting the time individuals remain opioid-free—offers a clinically meaningful complement to QALYs in
9min
Published in JCO Oncology Practice (October 2025), the ASCO-sponsored study by Kirkwood et al. provides the most comprehensive analysis to date of the U.S. hematology and medical oncology workforce, revealing growing geographic disparities and an aging clinician population that could worsen access to cancer care—especially in rural and socioeconomically vulnerable regions.Using Medicare Care Compare data from 2014, 2019, and 2
8min
TribeMD
A case report published in Frontiers in Endocrinology (October 2025) by Gandecka-Pempera et al. highlights a rare but severe complication of combined GLP-1 receptor agonist (GLP-1 RA) and SGLT-2 inhibitor (SGLT-2i) therapy — euglycemic diabetic ketoacidosis (euDKA) refractory to standard management.The case involved a 36-year-old man with newly diagnosed type 2 diabetes mellitus (T2DM), obesit
Endocrinology
8 out, 2025
Grupo Bipp
A preclinical investigation published in npj Parkinson’s Disease (2025) explored whether sublethal low-dose γ-radiation could induce Parkinson’s disease (PD)-related alterations in the substantia nigra (SN) of large mammals. Conducted at the Uniformed Services University (Bethesda, USA), the study used Göttingen minipigs to model human-like neuroanatomy and radiosensitivity.Fourteen animals were divided into a radiatio
Neurology
A study published in npj Parkinson’s Disease (2025) investigated whether subjective cognitive decline (SCD) represents an early marker of neurodegeneration in individuals with isolated REM sleep behavior disorder (iRBD) — a prodromal phase of α-synucleinopathies such as Parkinson’s disease (PD) and dementia with Lewy bodies (DLB).Using data from the CogTrAiL-RBD study at the University of Cologne, researchers analyzed
A multicenter Austrian study published in ESMO Open (2025) assessed the real-world performance of NALIRIFOX—a triplet chemotherapy combining nanoliposomal irinotecan, 5-fluorouracil/leucovorin, and oxaliplatin—in 80 patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). The findings confirm that NALIRIFOX retains strong clinical efficacy and a favorable safety profile outside clinical trial settings.After a median follow-up of 13.7
A landmark systematic review and meta-analysis led by L. F. C. de Almeida et al. and published in ESMO Open (2025) evaluated the strategy of maintaining cyclin-dependent kinase 4/6 inhibition beyond progression in hormone receptor–positive, HER2-negative advanced breast cancer (HR+/HER2– ABC). The study pooled data from five randomized controlled trials — MAINTAIN, PACE, PALMIRA, postMONARCH, and EMBER-3 — encompassing 1,184
Med.IQ
Medical Affairs
Browse our channels
